Fig. 3From: Could potentially calprotectin be a promising biomarker to oracle biologic therapy response in rheumatoid arthritis?Disease activity score 28 (DAS28) among the enrolled rheumatoid arthritis patients. There was a statistically significant decline in the mean DAS28 amongst RA patients from 5.91 ± 0.98 to 4.57 ± 1.08 ng/ml three months after initiation of biologic therapy (P < 0.001)Back to article page